• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature clinical practice. Rheumatology >Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis.
【24h】

Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis.

机译：奎纳普利在有限的皮肤全身性硬化症中对血管损伤的功效不足。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gliddon et al. conducted a randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy of the angiotensin-converting enzyme inhibitor quinapril for the management of vascular damage in systemic sclerosis (SSc). The trial comprised 213 patients with limited cutaneous SSc or Raynaud's phenomenon (mean age 54 years, 182 females) who were randomly assigned to receive 80 mg/day, or the maximum tolerated dose, of quinapril (n = 105) or placebo (n = 108) for 2-3 years. Patients were assessed every 3 months. The number of new ischemic digital ulcers was recorded as the primary end point, while the frequency of Raynaud's phenomenon episodes, skin score, health status, pulmonary artery pressure and treatments for ischemia were also monitored as secondary end points. There were no detectable differences between patients treated with quinapril and those receiving placebo; however, although no severe adverse effects were observed, patients taking quinapril experienced significantly moreadverse effects.
机译：Gliddon等。进行了一项随机，双盲，多中心，安慰剂对照的研究，以评估血管紧张素转换酶抑制剂奎那普利对系统性硬化症（SSc）血管损伤的处理的有效性。该试验包括213名皮肤SSc或雷诺氏现象受限的患者（平均年龄54岁，女性182名），他们被随机分配接受每天80毫克或最大耐受剂量的喹那普利（n = 105）或安慰剂（n = 108）2-3年。每3个月对患者进行一次评估。记录新发缺血性溃疡的数量为主要终点，同时监测雷诺现象发作的频率，皮肤评分，健康状况，肺动脉压和缺血治疗为次要终点。喹那普利治疗的患者与接受安慰剂的患者之间没有可检测到的差异。然而，尽管未观察到严重的不良反应，但服用奎那普利的患者的不良反应明显更多。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号